NCT04990349View on ClinicalTrials.gov

Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 9, 2022

Primary Completion Date

November 10, 2023

Study Completion Date

December 1, 2023

Conditions

Cardiogenic ShockExtracorporeal Membrane Oxygenation

Interventions

DRUG

Oxygen gas

Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.

Trial Locations (1)

Unknown

CHU de Besançon, Besançon

All Listed Sponsors

lead

Centre Hospitalier Universitaire de Besancon

OTHER

NCT04990349 - Normoxemic Versus Hyperoxemic Extracorporeal Oxygenation in Patients Supported by Veino-arterial ECMO for Cardiogenic Shock | Biotech Hunter | Biotech Hunter